Exosomal miR-320c: A Novel Biomarker for Atrial Cardiomyopathy.

IF 2.4 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Yangcheng Xue, Zhuoran Jia, Shichu Liang, Manyu Dai, Fang Liu, Jian Wu, Ren Zhao
{"title":"Exosomal miR-320c: A Novel Biomarker for Atrial Cardiomyopathy.","authors":"Yangcheng Xue, Zhuoran Jia, Shichu Liang, Manyu Dai, Fang Liu, Jian Wu, Ren Zhao","doi":"10.1007/s12265-025-10627-w","DOIUrl":null,"url":null,"abstract":"<p><p>Early diagnosis and treatment of atrial cardiomyopathy(ACM) are crucial for patients with atrial fibrillation(AF), and further exploration of its biomarkers remains necessary. High-throughput sequencing of exosomal miRNAs was performed on blood samples from patients with persistent AF (PeAF) exhibiting mild and severe left atrial fibrosis, with supraventricular tachycardia (SVT) patients. Quantitative real-time reverse transcription polymerase chain reaction analysis validated differentially expressed miRNAs (DE miRNAs) from severe left atrial fibrosis PeAF, SVT and health controls. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted on target genes. Four exosomal DE miRNAs were identified, including miR-5106, let-7e-5p, miR-320c, and miR-382-3p. Exosomal miR-320c was down-regulated in severe left atrial fibrosis PeAF patients, while the other three miRNAs showed no significant changes. Exosomal miR-320c emerges as a potential biomarker for severe left atrial fibrosis and ACM, suggesting its suitability as a therapeutic target.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12265-025-10627-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Early diagnosis and treatment of atrial cardiomyopathy(ACM) are crucial for patients with atrial fibrillation(AF), and further exploration of its biomarkers remains necessary. High-throughput sequencing of exosomal miRNAs was performed on blood samples from patients with persistent AF (PeAF) exhibiting mild and severe left atrial fibrosis, with supraventricular tachycardia (SVT) patients. Quantitative real-time reverse transcription polymerase chain reaction analysis validated differentially expressed miRNAs (DE miRNAs) from severe left atrial fibrosis PeAF, SVT and health controls. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted on target genes. Four exosomal DE miRNAs were identified, including miR-5106, let-7e-5p, miR-320c, and miR-382-3p. Exosomal miR-320c was down-regulated in severe left atrial fibrosis PeAF patients, while the other three miRNAs showed no significant changes. Exosomal miR-320c emerges as a potential biomarker for severe left atrial fibrosis and ACM, suggesting its suitability as a therapeutic target.

外泌体miR-320c:心房心肌病的新生物标志物
心房性心肌病(ACM)的早期诊断和治疗对心房颤动(AF)患者至关重要,进一步探索其生物标志物仍是必要的。研究人员对患有轻度和重度左心房纤维化并伴有室上性心动过速(SVT)的持续性房颤(PeAF)患者的血液样本进行了外泌体mirna的高通量测序。定量实时逆转录聚合酶链反应分析验证了重度左心房纤维化PeAF、SVT和健康对照者差异表达的miRNAs (DE miRNAs)。对目标基因进行基因本体和京都基因与基因组百科全书分析。鉴定了四种外泌体DE mirna,包括miR-5106, let-7e-5p, miR-320c和miR-382-3p。外泌体miR-320c在严重左心房纤维化PeAF患者中下调,而其他三种mirna无显著变化。外泌体miR-320c作为严重左心房纤维化和ACM的潜在生物标志物出现,表明其作为治疗靶点的适用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cardiovascular Translational Research
Journal of Cardiovascular Translational Research CARDIAC & CARDIOVASCULAR SYSTEMS-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
6.10
自引率
2.90%
发文量
148
审稿时长
6-12 weeks
期刊介绍: Journal of Cardiovascular Translational Research (JCTR) is a premier journal in cardiovascular translational research. JCTR is the journal of choice for authors seeking the broadest audience for emerging technologies, therapies and diagnostics, pre-clinical research, and first-in-man clinical trials. JCTR''s intent is to provide a forum for critical evaluation of the novel cardiovascular science, to showcase important and clinically relevant aspects of the new research, as well as to discuss the impediments that may need to be overcome during the translation to patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信